Neurolixis to present results of successful NLX-112 proof-of-concept clinical trial at the World Parkinson’s Congress – World News Report – Medical Marijuana Program Connection

Neurolixis to present NLX-112 results at Barcelona WPC meeting

A First-in-Class Highly Selective and Efficacious Serotonin 5-HT1A Receptor Agonist for treatment of Parkinson’s Disease

PARK RIDGE, NJ, UNITED STATES, June 27, 2023/EINPresswire.com/ — Neurolixis, Inc., a private, clinical-stage company developing innovative drug therapies for the treatment of neurologic and psychiatric disorders with high unmet medical needs, will be presenting detailed results of its – (befiradol) for treatment of levodopa-induced dyskinesias (LID) in Parkinson’s disease (PD). Neurolixis has previously announced (March 20, 2023) that NLX-112, a first-in-kind, highly selective serotonin 5 HT1A receptor agonist, met the primary outcome of safety and tolerability and, in addition, showed statistically significant efficacy in reducing LID symptoms in people with Parkinson’s (PwP). The company will now present the details of this clinical trial at the forthcoming World Parkinson’s Congress (WPC) in Barcelona, Spain (July 4-7, 2023), including…